Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion
Fig 6
The spatiotemporal distribution of radiopharmaceuticals in tumor interstitial space at (A) 500 min, (B) 1000 min, (C) 3000 min, (D) 6000 min, and (E) 30000 min post-treatment for patient 1.
(F) Different absorbed doses (due to contribution of peptides in interstitial space) calculated by PBPK vs. CDR models.